RE:RE:Please no more good news .Management knew exactly what they were doing with those PRs - providing buying support for presidents club members so they could offload shares and invest in the latest PR.
Cynical - absolutely but tell me I am wrong.
Finacing has been botched since the phase 2 raise in my humble opinion. The stock price has never recovered.
Not sure how the share price will react if they get their $5-$10 million raise and then do a shelf prospectus for many millions more.
Is it the Venture exchange, Roger or something else that is hindering acceptance of the technology and the results achieved to date. Perhaps it is the company track record of over promising and under delivering. Still waiting for BTD despite the August 2022 release the company expected it in Q4. How about up to 20 sites for the clinical trials when they only have 10. 68 patients treated to date and 100 expected by year end.